Epix Medical and InSightec of Israel have allied to investigate the use of Epix's vascular MRI contrast agent, MS-325, to facilitate the treatment of tumors under MRI guidance. InSightec develops devices and software for MRI-guided high-intensity focused
Epix Medical and InSightec of Israel have allied to investigate the use of Epix's vascular MRI contrast agent, MS-325, to facilitate the treatment of tumors under MRI guidance. InSightec develops devices and software for MRI-guided high-intensity focused ultrasound, an investigational method of heating and destroying tumors or tissue such as uterine fibroids with millimeter precision. The collaboration will initially focus on preclinical studies leading to future use in the image-guided therapy program at Brigham and Women's Hospital in Boston. Epix and InSightec will share information on their technologies to optimize the use of contrast agents during interventional procedures.
© 2001 Miller Freeman Inc.
3/28/01, Issue # 1506, page 4.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.